Please login to the form below

Not currently logged in
Email:
Password:

Samsung Bioepis

This page shows the latest Samsung Bioepis news and features for those working in and with pharma, biotech and healthcare.

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Under the deal, Biogen is taking exclusive rights to Samsung Bioepis’ SB11, a biosimilar of Novartis/Roche’s Lucentis (ranibizumab), as well as SB15 which is a version of ... Meanwhile, as a rider to the licensing deal, Biogen has also taken on

Latest news

  • Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan

    The ruling also delays the date on which Sandoz and Samsung Bioepis, which became the second company to win FDA approval for an Enbrel biosimilar in April, can begin recouping returns

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    The two new biosimilars will join products from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit in an assault on AbbVie’s market share for the

  • Hardy returns to Genentech as CEO Hardy returns to Genentech as CEO

    In the US, the FDA has already approved three Herceptin copycats – Celltrion and Teva’s Herzuma, Samsung Bioepis’ Ontruzant and Myland’s Ogivri, however the companies will have to wait until

  • Generic Differentiation Generic Differentiation

    And evolution predicts a fourth model, the ‘Frugal Followers’, that is not yet fully emerged but Samsung Bioepis looks like a contender to make very low-cost biosimilars.

  • First Humira biosimilars reach EU market First Humira biosimilars reach EU market

    Copycat versions of the TNF inhibitor  from Amgen, Samsung Bioepis/Biogen, Mylan/Fujifilm Kyowa Kirin, and Novartis’ Sandoz unit are starting to become available in their first EU markets now that ... Also already launched is Samsung Bioepis and

More from news
Approximately 16 fully matching, plus 38 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics